December 4, 2020

Top 5 ETF’s Outperforming Market

Midas Letter
Midas Letter
Top 5 ETF’s Outperforming Market

The big news of the day is the mass hospitalizations of new Coronavirus cases. Yesterday it was reported that U.S. hospitalizations surpassed 100,000 for the first time. This pressure on healthcare threatens the entire system.

Meanwhile, U.S. stocks have continued their uptrend this week. The NASDAQ-100 (INDEXNASDAQ: NDX) and S&P 500 Index (INDEXSP: .INX) hitting highs. Although cases are climbing fast, the main stock market catalyst is that the first vaccine shots could be administered in less than two weeks.

The economy, unlike the markets, has been greatly impacted by this awful virus. Jobless claims reportedly dropped today, but there are still 712,000 people in the country out of employment. However, it is estimated that the U.S.added 440,000 jobs last month.

The weakness and confusion in the healthcare sector could be what lawmakers need to compromise on a coronavirus relief stimulus package before the holidays.

Watch the full interview as we take a look under the hood of the major U.S. indices on the back of all this news.

P.S. We also give five ETF’s in the work-from-home space taking advantage of all the catalysts we’ve just mentioned.


Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.